Gilead Sciences Announces Second Quarter 2021 Dividend FOSTER CITY, Calif. (BUSINESS WIRE)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021. The dividend is payable on June 29, 2021, to stockholders of record at the close of business on June 15, 2021. Future dividends will be subject to Board approval. About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021
Gilead Sciences, Inc. announced today that its first quarter 2021 financial results will be released on Thursday, April 29, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s first quarter 2021 financial results and will provide a business update. A live webcast of the call can be accessed at Gilead’s Investors page at or by dialing … Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2021 financial results will be released on Thursday, April 29, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s first quarter 2021 financial results and will provide a business update.
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1PD-L1 Inhibitor – – New Indication Marks Second FDA Approval for Trodelvy in 2021 – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of Trodelvy ® for use in adult patients with locally advanced or metastatic …
Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1PD-L1 Inhibitor – – New Indication Marks Second FDA Approval for Trodelvy in 2021 –
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study – – Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted full approval to Trodelvy ® for adult patients with …
Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study – – Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis